Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Nanostart-holding MagForce successfully implements capital increase in the amount of € 33.5 mn

Abstract:
- New funding secures financing of post-marketing trial of the NanoTherm® therapy in glioblastoma and FDA filing
- Next cancer indication in clinical development will be prostate cancer

Nanostart-holding MagForce successfully implements capital increase in the amount of € 33.5 mn

Berlin / Frankfurt Germany | Posted on March 20th, 2013

Nanostart-holding MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of nanomedicine with focus on oncology, today announced that it has successfully completed a capital increase against cash and non-cash contributions including preemptive rights in the total amount of €33.5 million.

In total, 18,606,553 new no-par value bearer shares have been subscribed. Thereof 9,750,846 new shares have been subscribed against cash and 8,855,707 new shares have been subscribed against a contribution in kind, namely converting €15.9 million shareholder loans into equity. As a result, MagForce is debt-free and has €17.6 million cash on hand to drive the company through the next inflection points.

Prof. Hoda Tawfik, COO and co-CEO of MagForce, comments: "With this capital increase, MagForce is entering a new phase. With the successful capital increase we have set the preconditions for establishing the NanoTherm® therapy in the medical community and for achieving the validation of the clinical data in Europe as well as for approaching filing for approval in the USA with the FDA. This will be achieved substantially via the announced post-marketing clinical trial with glioblastoma patients. Additionally, we will further develop the NanoTherm® therapy in other oncology indications e.g. prostate cancer, the second most frequently diagnosed cancer of men and the fifth most common cancer overall." Christian von Volkmann, CFO and co-CEO of MagForce, adds: "The successful capital increase with considerable size shows the trust and confidence international institutional investors put into the MagForce technology and the MagForce team. The company now has secured sufficient funding from renowned international investors to reach the next inflection points and is well prepared for a time of dynamic growth."

Marco Beckmann, CEO of Nanostart, adds: "We congratulate the MagForce team on this successful transaction, and are pleased that long-term financing of MagForce has been secured. The company now has the necessary financial resources to implement its planned strategy and demonstrate its strengths."

Nanostart did not use its subscription rights in the capital increase. The company's stake amounts to around 10% after the transaction.

In recent years, Nanostart has been the main source of financing for MagForce. This has significantly hampered its flexibility in terms of entering into new investments. Nanostart sold its receivables of €16.1 mn relating to MagForce to an investor at the end of 2012. The newly gained financial scope is to be used to initiate new projects.

####

About Nanostart AG
Nanostart AG is a leading nanotechnology venture capital company. The company invests venture capital (VC) in promising young nanotechnology companies. Nanostart invests globally and at different phases of development. Emphasis of investments is on especially innovative industries such as cleantech, life sciences, and IT/electronics. Nanostart invests either directly in nanotechnology companies or through a regional nanotechnology fund. The headquarters of Nanostart AG is in Frankfurt, Germany.

About MagForce:

MagForce AG is a leading medical technology company in the field of nanomedicine in oncology. The Company's proprietary, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm®, NanoPlan®, and NanoActivator™ are trademarks of MagForce AG in select countries. For more information, please visit www.magforce.com.

Disclaimer:

This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia, or Japan.

For more information, please click here

Contacts:
Nanostart AG
Dr. Hans Joachim Dürr
Head of Corporate Communications
Goethestrasse 26-28
60313 Frankfurt/Main
P: +49 69-21 93 96 111
F: +49 69-21 93 96 150

Copyright © Nanostart AG

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Basel physicists develop efficient method of signal transmission from nanocomponents May 23rd, 2015

This Slinky lookalike 'hyperlens' helps us see tiny objects: The photonics advancement could improve early cancer detection, nanoelectronics manufacturing and scientists' ability to observe single molecules May 23rd, 2015

Visualizing How Radiation Bombardment Boosts Superconductivity: Atomic-level flyovers show how impact sites of high-energy ions pin potentially disruptive vortices to keep high-current superconductivity flowing May 23rd, 2015

Conversion of Greenhouse Gases to Syngas in Presence of Nanocatalysts in Iran May 22nd, 2015

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

BESSTECH Announces $250K Investment from Eastern New York Angels : Funding will accelerate commercialization of BESSTECH’s innovative lithium-ion battery electrode technology and enable hiring of key personnel May 13th, 2015

Harris & Harris Group Portfolio Company OpGen Raises $17.1 Million in Initial Public Offering May 6th, 2015

Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015

Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015

Investments/IPO's/Splits

Evident Thermoelectrics Acquires GMZ Energy: Investment Accelerates Launch Of Evident's Thermoelectric Modules For Waste Heat May 20th, 2015

Nanometrics Announces Live Webcast of Upcoming Investor and Analyst Day May 20th, 2015

PEN Inc. Announces First Quarter Financial Results: Investor Webcast and Business Update Set for May 21, 1 pm EDT May 13th, 2015

Harris & Harris Group Portfolio Company OpGen Raises $17.1 Million in Initial Public Offering May 6th, 2015

Nanomedicine

New Antibacterial Wound Dressing in Iran Can Display Replacement Time May 22nd, 2015

Researchers develop new way to manufacture nanofibers May 21st, 2015

Effective Nano-Micelles Designed in Iran to Treat Cancer May 20th, 2015

Nature inspires first artificial molecular pump: Simple design mimics pumping mechanism of life-sustaining proteins found in living cells May 19th, 2015

Announcements

Basel physicists develop efficient method of signal transmission from nanocomponents May 23rd, 2015

This Slinky lookalike 'hyperlens' helps us see tiny objects: The photonics advancement could improve early cancer detection, nanoelectronics manufacturing and scientists' ability to observe single molecules May 23rd, 2015

Visualizing How Radiation Bombardment Boosts Superconductivity: Atomic-level flyovers show how impact sites of high-energy ions pin potentially disruptive vortices to keep high-current superconductivity flowing May 23rd, 2015

New Antibacterial Wound Dressing in Iran Can Display Replacement Time May 22nd, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project